Media headlines about Checkpoint Therapeutics (NASDAQ:CKPT) have trended somewhat positive on Sunday, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Checkpoint Therapeutics earned a daily sentiment score of 0.13 on Accern’s scale. Accern also assigned news stories about the company an impact score of 47.6672006988645 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the news stories that may have effected Accern Sentiment Analysis’s scoring:
- Zacks: Checkpoint Therapeutics Inc (CKPT) Given $15.50 Average Target Price by Brokerages (americanbankingnews.com)
- Small-Cap Snapshot: Fitness drink maker Celsius Holdings hits 52-week low after 2Q disappoints (proactiveinvestors.com)
- Checkpoint Therapeutics up 23% (seekingalpha.com)
- HC Wainwright Reiterates “Buy” Rating for Checkpoint Therapeutics (CKPT) (americanbankingnews.com)
- Checkpoint Therapeutics (CKPT) Posts Quarterly Earnings Results, Beats Expectations By $0.09 EPS (americanbankingnews.com)
CKPT has been the topic of a number of analyst reports. HC Wainwright restated a “buy” rating and issued a $11.00 price objective on shares of Checkpoint Therapeutics in a report on Wednesday. Zacks Investment Research lowered shares of Checkpoint Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, May 11th. Finally, ValuEngine upgraded shares of Checkpoint Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd.
Checkpoint Therapeutics (NASDAQ:CKPT) last announced its quarterly earnings results on Tuesday, August 7th. The company reported ($0.23) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.32) by $0.09. Checkpoint Therapeutics had a negative net margin of 2,367.51% and a negative return on equity of 126.68%. The firm had revenue of $0.13 million for the quarter, compared to analyst estimates of $0.37 million. equities research analysts expect that Checkpoint Therapeutics will post -1.18 EPS for the current year.
About Checkpoint Therapeutics
Checkpoint Therapeutics, Inc, an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's products include CK-301 in Phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC); and CK-101 in the Phase 1 portion of a Phase 1/2 clinical trial for the treatment of epidermal growth factor receptor (EGFR) mutation-positive NSCLC.
See Also: What is the Book Value of a Share?
Receive News & Ratings for Checkpoint Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.